Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback